What Is TRH? Benefits, Research & Safety

The search for hypothalamic releasing factors began in the 1950s, based on evidence that the hypothalamus controlled pituitary function through chemical messengers. Roger Guillemin and Andrew Schally led competing research programs. TRH was the first releasing hormone to be identified and characterised. In 1969-1970, both Guillemin's and Schally's groups independently determined its structure as a simple tripeptide (pyroglutamyl-histidyl-prolineamide). The simplicity of TRH's structure was surprising—a tripeptide controlling a major hormone axis. Its characterisation opened the door to identifying other releasing hormones (GnRH, GHRH, CRH, somatostatin) and established neuroendocrinology as a field. Guillemin and Schally shared the Nobel Prize in Physiology or Medicine in 1977 for their discoveries concerning "the peptide hormone production of the brain." Clinical applications developed for TRH as a diagnostic agent (TRH stimulation test) for pituitary-thyroid disorders. Research also explored therapeutic uses in depression and neurological conditions, though with limited translation to practice. TRH analogues with improved stability have been developed and studied for conditions including amyotrophic lateral sclerosis (ALS) and spinocerebellar degeneration, with some approved in Japan for these indications.